Raymond A Farkouh

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. pmc Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
    Stephanie R Earnshaw
    RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USA
    BMC Infect Dis 12:101. 2012
  2. pmc Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
    David R Strutton
    Vaccines Market Access and Outcomes Research Specialty Care Business Unit, Pfizer Inc, 500 Arcola Road, Dock D, COL D4555, Collegeville, PA 19426 3930, USA
    BMC Infect Dis 12:175. 2012
  3. doi request reprint Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions
    Raymond A Farkouh
    Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA
    Expert Rev Vaccines 11:1235-47. 2012
  4. doi request reprint Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands
    David R Strutton
    Pfizer Inc, Collegeville, PA 19426, USA
    J Infect 64:54-67. 2012

Collaborators

  • Rogier M Klok
  • Maarten J Postma
  • Jaime L Rubin
  • David R Strutton
  • Stephanie R Earnshaw
  • Ulrike Theidel
  • Paul M Loiacono
  • Steven I Pelton
  • Sharon Hwang
  • Cheryl L McDade
  • Stathis Kontodimas
  • David Strutton
  • Giovanni Zanotti
  • Sotiria Papanicolaou
  • Kristen E Gilmore
  • Milton C Weinstein
  • Keith P Klugman
  • Lisa J McGarry

Detail Information

Publications4

  1. pmc Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada
    Stephanie R Earnshaw
    RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC 27709, USA
    BMC Infect Dis 12:101. 2012
    ..We examined public health and economic impacts of a PCV10 and PCV13 pediatric national immunization programs (NIPs) in Canada...
  2. pmc Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data
    David R Strutton
    Vaccines Market Access and Outcomes Research Specialty Care Business Unit, Pfizer Inc, 500 Arcola Road, Dock D, COL D4555, Collegeville, PA 19426 3930, USA
    BMC Infect Dis 12:175. 2012
    ..Analysis of US claims data from April 2010 to June 2011 estimated that 39% of the 13-valent pneumococcal conjugate vaccine (PCV13) catch-up eligible cohort would ever receive the catch-up vaccination; a previous analysis assumed 87%...
  3. doi request reprint Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions
    Raymond A Farkouh
    Pfizer Inc, 500 Arcola Road, Collegeville, PA 19426, USA
    Expert Rev Vaccines 11:1235-47. 2012
    ..These assumptions are discussed with regard to the validity of supporting data and implications on decision-making...
  4. doi request reprint Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands
    David R Strutton
    Pfizer Inc, Collegeville, PA 19426, USA
    J Infect 64:54-67. 2012
    ..Two new PCVs have been launched, a 10-valent vaccine (PCV10) and a 13-valent vaccine (PCV13). We examined public-health and economic impacts of PCV pediatric national immunization programs (NIPs) in Germany, Greece, and the Netherlands...